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Abstract The present work describes the development and
validation of a highly sensitive analytical method for the
simultaneous determination of 68 compounds, including illicit
drugs (opiates, opioids, cocaine compounds, amphetamines,
and hallucinogens), psychiatric drugs (benzodiazepines, bar-
biturates, anesthetics, antiepileptics, antipsychotics, antide-
pressants, and sympathomimetics), and selected human me-
tabolites in influent and effluent wastewater (IWWand EWW)
by liquid chromatography coupled to tandem mass spectrom-
etry (LC–MS/MS). The method involves a pre-concentration
and cleanup step, carried out by solid-phase extraction (SPE)
using the adsorbent Strata-XC, followed by the instrumental
analysis performed by LC–MS/MS, using a Kinetex
pentafluorophenyl (PFP) reversed-phase fused-core column
and electrospray ionization (ESI) in both positive and negative
modes. A systematic optimization of mobile phases was per-
formed to cope with the wide range of physicochemical prop-
erties of the analytes. The PFP column was also compared
with two reversed-phase columns: fused-core C18 and XB-
C18 (with a cross-butyl C18 ligand). SPE optimization and
critical aspects associated with the trace level determination of
the target compounds (e.g., matrix effects) have been also
considered and discussed. Fragmentation patterns for all the
classes were proposed. The validated method provides abso-
lute recoveries between 75 and 120 % for most compounds in
IWW and EWW. Low method limits of detection were
achieved (between 0.04 and 10.0 ng/L for 87 % of the com-
pounds), allowing a reliable and accurate quantification of the
analytes at trace level. Themethod was successfully applied to
the analysis of these compounds in five wastewater treatment
plants in Santorini, a touristic island of the Aegean Sea,
Greece. Thirty-two out of 68 compounds were detected in
all IWW samples in the range between 0.6 ng/L (for
nordiazepam) and 6,822 ng/L (for carbamazepine) and 22
out of 68 in all EWW samples, with values between 0.4 ng/
L (for 9-OH risperidone) and 2,200 ng/L (for carbamaze-
pine). The novel methodology described herein maximizes
the information on the environmental analysis of these sub-
stances and also provides a first profile of 68 drugs in a Greek
touristic area.
Keywords Illicit drugs . Psychiatric drugs .Wastewater .
LC–MS/MS . SPE
Introduction
From the first import into Europe of cannabis as a therapeutic
drug, in the nineteenth century byO’Shaugnessy (1838–1839)
[1], until the present time, the usage profile of psychotropic
and illicit drugs has changed dramatically. The progress of
medical science, the great development of chemistry and
pharmaceutical companies, and also the changes in social
conditions have led to a large growth of the number and use
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of psychotropic substances. According to the European
Monitoring Centre for Drugs and Drug Addiction
(EMCDDA 2012) estimations [2], 42.5 million Europeans
(between 15 and 34 years old) had smoked cannabis at least
once (10.8 % in Greece), 8 million had consumed cocaine
(1.0% in Greece), 7.0 million had taken amphetamines (0.2%
in Greece), and 7.5 million had used ecstasy (0.6 % in
Greece). The consumption of psychiatric drugs has also in-
creased a lot during the last years as a consequence of the
increased financial European crisis, which can lead to psycho-
logical health effects causing several psychiatric diseases [3,
4]. Psychiatric and illicit drugs have become pseudo-persistent
in the environment due to their high volumes of production
and use, and nowadays, they are considered environmental
emerging contaminants [5–7]. Following consumption, these
compounds and their metabolites are continuously discharged
into wastewaters due to human excretion after legal or illegal
consumption or occasional direct disposal of clandestine lab-
oratory wastes into sewage systems [8, 9]. These substances
and related metabolites (since they are partly metabolized) are
continuously released into the aquatic environment through
effluent wastewaters (EWW) due to their partial elimination in
sewage treatment plants [6–8, 10, 11]. These compounds are
biologically active and have been designed to exert specific
effects on organisms. Despite low concentrations, the effects
of these substances in the environment and human health
cannot be excluded. Substances such as cocaine, morphine,
or var ious amphetamines such as ecs tasy (3,4-
methylenedioxy-N-methylamphetamine (MDMA)) have
powerful pharmacological effects, and their presence as mix-
tures in superficial waters may cause toxic effects on aquatic
organisms [7, 10, 12, 13]. Substances like the selective sero-
tonin reuptake inhibitors (SSRIs) and serotonin–norepineph-
rine reuptake inhibitors (SNRIs), venlafaxine, paroxetine, and
fluoxetine, with a high consumption rate along the population
of Europe, are listed in the top-ten list of the most harmful
psychoactive drugs [14].Moreover, recent results also showed
clear cyto-genotoxic effects of some drugs (e.g., cocaine) in
common nontarget organism, highlighting the risk of illicit
drugs in the ecosystem [15].
Different groups of illicit, stimulant, and psychiatric drugs,
including opiates and opioids, hallucinogens, barbiturates,
antipsychotics, sedatives, or antidepressants, have been de-
tected in urban wastewater and surface water (lake and river
water) from Germany [16], Spain [17–29], USA and Canada
[8, 9, 30–32], France [33], Ireland [34], Belgium [6, 35, 36],
UK [37–39], Netherlands [40] Italy, and Switzerland [10–12,
41, 42].
In recent years, several authors have developed analytical
methodologies to determine psychoactive pharmaceuticals,
illicit drugs, and their metabolites in superficial water and
wastewater with the objective of monitoring their environ-
mental occurrence and also to estimate drug usage at the
community level. Liquid chromatography coupled to tandem
mass spectrometry (LC–MS/MS) is the most used technique
for the analysis of these substances in the aquatic environment
due to its versatility, specificity, and selectivity [6, 10–12,
16–23, 25–44]. Most of these methodologies used C18
reversed-phase column, and only one among them used a
pentafluorophenyl (PFP) revered-phase column [43] provid-
ing results just for a small number of polar compounds. The
PFP stationary phase incorporates fluorine atoms on the pe-
riphery of the phenyl ring to provide a unique aromatic and
polar selectivity.
The main objective pursued within the study was to devel-
op and validate a multi-analyte method for the simultaneous
determination of 68 different psychoactive pharmaceuticals
and illicit drugs and their metabolites (a particular mixture of
compounds with very different physicochemical properties) in
municipal wastewaters using a PFP column for their separa-
tion. Compromised LC–electrospray ionization (ESI)–MS/
MS conditions for the 68 target compounds were provided,
as well as proposed fragmentation patterns for all compounds.
The main difficulties of this study include the wide range of
polarities of the compounds, the zwitterionic character, and
different chemical characteristics [45] and also the multi-trace
concentration levels that are usually detected. To overcome
these difficulties, a rigorous optimization of sample prepara-
tion, mobile and stationary phases, and solid-phase extraction
(SPE) sorbents as well as ESI–MS condition optimizations
were performed. The developed methodology was applied for
the determination, for the first time in Greece, of the presence
of psychoactive pharmaceuticals, illicit drugs, and their me-
tabolites in wastewater. The occurrence of these substances
was evaluated in five wastewater treatment plants (WWTPs)
located in Santorini, a touristic island of the Aegean Sea.
Materials and methods
Chemicals and reagents
Up to 68 drugs and metabolites, belonging to opiates, opioids
and their metabolites (7), cocaine and metabolites (3), am-
phetamines (5), hallucinogens (cannabinoids (2)), lysergic
acid diethylamide (LSD) (2), benzodiazepines (13), barbitu-
rates (2), anesthetics (6), antiepileptics (7), antipsychotics (6),
antidepressants (tricyclic (5), tetracyclic (2)), SSRIs (5),
SNRIs (1), and sympathomimetics (2) were determined by
LC–ESI–MS/MS. Some features of the studied compounds
including analyte name, Chemical Abstracts Service number,
chemical structure, molecular formula, molecular weight, pKa
and log-Kow are shown in Electronic Supplementary Material
Table S1.
High-purity individual standards (>98 %), solutions or
solids, of all the target analytes were purchased from LGC
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Promochem (Molsheim, France) except topiramate and
lamotrigine, which were obtained from Glenmark (Mahwah,
NJ, USA) and Sigma Aldrich Chemie GmbH (Steinheim,
Germany), respectively. All deuterated compounds were also
obtained from LGC Promochem (Molsheim, France):
morphine-D3 (MOR-D3), codeine-D3 (COD-D3), cocaine-
D3 (COC-D3) , 2 - e thy l idene -1 ,5 -d ime thy l -3 ,3 -
diphenylpyrrolidine-D3 (EDDP-D3), ecgonine methyl ester-
D3 (EME-D3), 3,4-methylenedioxy-N-methylamphetamine-
D5 (MDMA-D5), 3,4-methylenedioxy amphetamine-D5
(MDA-D5), tetrahydrocannabinol-D3 (THC-D3),
tetrahydrocannabinolic acid-D3 (THCA-D3), and lysergic ac-
id diethylamide-D3 (LSD-D3). Individual stock solutions
were prepared in either acetone or methanol (MeOH), at
concentrations varying between 10 and 1,250 mg/L.
Solutions for direct injection (infusion) of individual standards
and internal standards (IS) were prepared at concentrations of
2 mg/L in acetonitrile (ACN)/water (50:50, v/v), just before
direct injection experiments.Working solutions were prepared
daily by appropriate dilution of the mixture stock standard and
IS solutions in MeOH.
Calibration standards were prepared by serial dilution of
the mixed working solution using Milli-Q water resulting in
individual concentrations ranging from 1 to 100 μg/L All
stock and working solutions were stored in glass bottles in
the dark at −20 °C. MeOH and ACN (both of LC–MS
quality, 99.9 % purity, Lichrosolv), were purchased from
Merck (Darmstadt, Germany). High-purity water was pre-
pared using a Milli-Q water purification system (Millipore
Direct-Q UV, Bedford, MA, USA). Formic acid (98 %
purity, HPLC grade) was obtained from Sigma-Aldrich
(Fluka, Germany). Hydrochloric acid (HCl) (37 %) was
purchased from Merck (Darmstadt, Germany), and ammo-
nium hydroxide was prepared using ammonia (25 %), which
was purchased from Panreac (Barcelona, Spain). Strata-X
(200 mg/6 mL) and Strata-XC (200 mg/6 mL) cartridges and
syringe filters (RC) of 4 mm and with pore size of 0.2 μm
were obtained from Phenomenex (Torrance, CA, USA).
Glass fiber filters (GFF, pore size 0.7 μm) used in
wastewater filtration were obtained from Millipore (Cork,
Ireland).
Sample collection
Santorini is an island located in the southern Aegean Sea,
about 200 km southeast from Greece’s mainland. It forms
the southernmost member of the Cyclades group of islands
and covers an area of 73 km2. The census population (data
from 2011) is 15,550 inhabitants, but since this island is a very
important touristic center, its population increases very con-
siderably during summer periods. Santorini is, along with
Anafi Island, the only location in Europe to feature a hot
desert climate according to the Köppen climate classification
system [46], and most of the water used for human activities
comes from desalination plants.
Influent and effluent wastewater samples (grab samples)
were collected from five WWTP networks at Santorini
Island. Sampling locations are described in detail in Fig. 1.
Emporio and Ia are the most populated areas in the island of
Santorini, especially during the summer period, when the
sampling was carried out (July 2012). The main character-
istics of the five WWTP are summarized in Table 1. As the
table shows, all the WWTP that were investigated are
equipped with conventional activated sludge (CAS) second-
ary treatment.
Wastewater samples (both IWW and EWW) were col-
lected in plastic (PET) bottles (volume 1.5 L) and main-
tained at chilled conditions until their arrival at the labora-
tory. After transportation, the samples were directly stored
(at 4 °C).
Sample pretreatment and solid-phase extraction
Upon reception in the laboratory, samples were vacuum fil-
tered through GFF. Sample pH was adjusted to 2.5 after
filtration using HCl (1 M) in order to prevent the degradation
of the analytes bymicroorganisms and to facilitate the positive
ionization when working with positive electrospray. Internal
standards (50 μL of a methanolic mixture containing 1 mg/L
of each deuterated compound) were added to the samples
prior to the SPE step in the optimized final method. The
extractions of samples were carried out within 24 h from their
arrival in the laboratory and the analysis of extracts, within
7 days after extraction (during this period of days, the extracts
were stored in the dark at −20 °C). These storage conditions
were chosen based on some studies regarding the stability of
the target compounds [47, 48].
In the present study, we compared two different polymeric
sorbents, Strata-X (hydrophilic-lipophilic reversed phase) and
Strata-XC (strong cation exchange and hydrophilic-lipophilic
reversed phase). In the optimized methodology, the Strata-XC
polymeric sorbent cartridge (200 mg/6 mL) was selected to
perform the SPE step. The SPE procedure was derived from
Bisceglia et al. [30] with modifications. Figure 2 shows the
SPE procedure with Strata-XC (the optimized methodology)
and also with Strata-X (finally discarded). In the optimized
method, the cartridges were conditioned with 6 mL of meth-
anol and 6 mL of acidified ultrapure water (pH 2.5 with HCl
1 M). Next, 50-mL samples (pH 2.5) were loaded under
gravity. The cartridges were washed with 3 mL of ultrapure
water (pH 2.5) and subsequently dried under vacuum for 1 h
and 8 psi. Analytes were eluted with 3×2 mL of 2 % NH3 in
methanol (pH~10) and, after evaporation to dryness under a
constant stream of nitrogen at 40 °C, extracts were
reconstituted in 500 μL of 54 % MeOH (aq) followed by a
1-min vortex stirring.
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LC–MS/MS analysis
Chromatographic separation was performed using an Accela
gradient UHPLC pump equippedwith anAccela Autosampler
system from Thermo Electron Corporation (Thermo, San
Jose, CA, USA). Separation of the compounds, after mobile
phase and column optimization, was achieved on a Kinetex
PFP reversed-phase fused-core column (50 mm×2.10 mm,
1.7 μm) equipped with a guard PFP column (4 mm×20 mm).
In the analysis with electrospray positive ionizationmode (PI),
the mobile phase was composed of Milli-Q water and MeOH
as organic phase, both containing 0.05 %v/v formic acid. The
adopted elution gradient starts with 2 % of MeOH and keeps
constant during 3min. After that, it increases linearly to 100%
in 20 min. Pure organic conditions were kept constant for
26 min, and finally initial conditions were reached and kept
constant for 16 min for column equilibration. The total run
time for each injection was 65 min. The column temperature
was kept constant at 25 °C. For the analysis under negative
ionization mode (NI), the determination of the analytes was
performed also on a Phenomenex™ Kinetex PFP column.
The mobile phase was composed of Milli-Q water and
MeOH. The gradient program starts with 30 % of MeOH for
3 min, increases linearly to 100 % in 20 min, keeps constant
for 7 min, and returns to initial conditions followed by 5 min
of equilibration time. The total run time for each injection was
35 min. The mobile phase flow rate was set to 100 μL/min,
and the injection volume was 10 μL in both ionization modes.
Mass spectrometry analysis was performed with a TSQ
Quantum Access triple-quadrupole mass spectrometer from
Thermo Electron Corporation (Thermo, San Jose, CA, USA)
equipped with an electrospray ionization source (Thermo
IonMAX). After optimization, 63 compounds were detected
in PI and 5 compounds in NI (Table 2). Identification and
quantification were performed under selected-reaction moni-
toring (SRM) mode. Two characteristic fragments of the pre-
cursor molecular ion were monitored for each target analyte.
The most abundant transition (precursor/product ion 1) was
used for quantification, whereas the second transition (precur-
sor/product ion 2) was used for confirmation. This procedure
was in compliance with the European Council Directive
2002/657/EC, that although it was initially conceived for food
residue analysis, it has been accepted by the scientific com-
munity for environmental analysis. Table 2 shows the frag-
mentation voltage and collision energies optimized for each
transition. For the PI and NI modes, ESI conditions were
Fig. 1 Location of the main
urban areas and sampling sites for
influent and effluent wastewaters
in Santorini
Table 1 Characteristics of the
wastewater treatment plants
(WWTP) investigated
Sampling date: 26 Jul 2012;
Primary settling: grinding,
desanding and sedimentation;
Type of sewage water treated:
urban
WWTP Mean influent flow
rate (m3/day)
Population
served
Average sludge
production (kg/
day)
Primary
treatment
Secondary
treatment
Kamari 1,600 15,500 3,500 Primary settling Activated sludge
Fira 1,500 10,500 2,900 Primary settling Activated sludge
Karterados 900 3,150 580 Primary settling Activated sludge
Emporio 600 3,000 390 Primary settling Activated sludge
Ia 700 6,000 1,000 Primary settling Activated sludge
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obtained as a compromise using the optimum values for most
compounds. A detailed description of optimum MS source
conditions as well as the total ion chromatographs in both
ionization modes are presented in Electronic Supplementary
Material Table S2. Instrument control and data acquisition and
evaluation were performed with Excalibur software (Thermo
Electron Corporation).
Method validation
The quantification of compounds in samples was performed
using spiked samples with the corresponding labeled analyte.
The linearity of the method was studied by analyzing standard
solutions in quadruplicate at concentrations ranging from 0.1
to 100 μg/L (seven-point calibration curve) for all the com-
pounds. Standard addition curves were also prepared at the
same concentration range. The method limits of detection
(MLOD) and the limits of quantification (MLOQ) were cal-
culated by analyzing five times the lowest spiked concentra-
tion (for most of the compounds 0.01 μg/L). For compounds
with high concentrations in influents (like codeine, THCA,
EME, citalopram, antiepileptics, venlafaxine, ephedrine, or
doxepin), replicate analyses of the same sample were per-
formed. MLODs were calculated as follows: the standard
deviation of the lowest spiked concentration or the standard
deviation of the replicate analyses (for abundant compounds)
was multiplied by 3 and then divided by the slope of the
calibration curve of spiked samples. The trueness of the meth-
od was assessed by spiking experiments at one concentration
level, 1.0 μg/L in both influents and effluents. The recovery
was calculated by comparing the response in extracted
wastewater samples spikedwith standard solutions at the same
concentration before (B) and after (A) the extraction: REC
(%)=B/A×100. Overall method repeatability was evaluated
by spiking wastewater samples with 1.0 μg/L of each com-
pound (n=6).Matrix effects (ME, %)were assessed according
to the equation ME (%)=[(A/C)−1]×100, where C is the
response obtained in neat standard solutions, and A is the
corresponding response for post-extraction spiked samples.
Nonspiked samples were measured in parallel, and their signal
was subtracted from the spiked ones.
Results and discussion
SPE procedure
Sample pre-concentration and purification of the target
analytes are critical steps and contribute very significantly to
the final performance of the analytical method. Target analytes
of the present work show very different physicochemical
properties, as it is shown in Electronic Supplementary
Material Table S1. The studied drugs are in general basic
compounds. The major microspecies at pH 2.5 for most
compounds are positively charged [45]. Opiates are charac-
terized by a NH+ charged group. Amphetamines, antidepres-
sants, SSRIs, SNRIs, antipsychotics, LSD hallucinogens, and
anesthetics (except thiopental, which is not charged) are also
positively charged at pH 2.5, with one or two NH+ groups.
Benzodiazepines at pH 2.5 have both neutral and positive
microspecies, since they may accept a proton at the amine
group. Oxazepam, lorazepam, and temazepam are an
Fig. 2 Flow chart of the SPE
procedures using both cartridges
(Strata-X and Strata-XC)
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exception in this group and are not charged. Other families of
compounds, including antiepileptics, cannabinoids, and bar-
biturates, are also neutral at this pH [45, 49]. In order to deal
with these significantly different physicochemical properties,
it was necessary to reach a compromise which provided good
recovery rates for most compounds.
Two types of poly-vinyl-3-piperidone-divinylbenzene
polymeric SPE cartridges, Strata-X (with neutral polymeric
sorbent), and its sulfonated analog, Strata-XC, were tested for
the determination of the target compounds. Strata-XC has
been successfully previously employed to pre-concentrate
basic illicit drugs from wastewater [30, 34, 43], whereas
Strata-X has never been used for the determination of drugs.
Strata-X cartridges provided absolute recoveries above 80 %
for most compounds (60), only three compounds showed
recoveries between 60 and 79 %, and six compounds lower
than 59 % (experiments performed with IWW). EME, an
important cocaine metabolite, was not possible to retain with
this cartridge. Strata-XC cartridges provided absolute recov-
eries above 80 % for 56 compounds (including EME), be-
tween 60 and 79 % for 6 compounds, and lower recoveries
than 59 % for 6 compounds, as it is shown in Fig. 3. Figure 4
shows a comparison of the obtained absolute recoveries for
some relevant selected compounds (IWW). Most of them
showed similar recovery rates with both approaches. It was
also observed that cannabinoids showed low but very repro-
ducible recoveries (relative standard deviation (RSD) values
<10% for all compounds) using both cartridges. For these
compounds, recoveries were higher with Strata-XC (although
with no significant statistical differences taking into account
the RSD values) because the two nonaromatic fused rings of
the cannabinoids as well as the alkyl side chain of the THC-
COOH structure are able to interact more strongly through
dispersive and pi–pi interactions with the divinylbenzene nu-
cleus of Strata-XC in comparison with Strata-X [50].
Detection of EME, which was only possible using Strata-
XC, is of capital importance because it is an important metab-
olite, along with benzoylecgonine (BECG), of cocaine, and it
is necessary in order to obtain solid consumption data of this
drug. The proposed final cartridge for further application of
the method after a certain compromise was Strata-XC. This
cartridge showed better hydrophobic as well as polar retention
characteristics, especially for EME and other polar metabo-
lites, compared to the neutral polymer with the same backbone
structure, Strata-X. Moreover, it provides lower matrix effect
for most of the compounds studied.
Vacuum pressure is also an important parameter during the
SPE process, especially at high pressures. It was observed that
when applying more than 10 psi, different compounds, in-
cluding morphine, 6-MAM, buprenorphine, EDDP, OC, 8-
OH mirtrazepam, nordiazepam, and flunitrazepam, showed
significantly lower recoveries than the ones obtained applying
8 psi, which was determined as the optimum value to perform
the SPEs.
Optimization of liquid chromatography
Different experiments were carried out in order to evaluate the
analyte retention times, peak shapes, and sensitivity during the
chromatography procedure. Three different LC columns were
evaluated: Kinetex PFP reversed-phase fused-core column
(50 mm×2.10 mm, 1.7 μm), Kinetex reversed-phase fused-
core C18 column (100 mm×2.10 mm, 2.6 μm), and Kinetex
C18-XB column (100 mm×2.10 mm, 2.6 μm), all from
Phenomenex™. Different mobile phases and gradient condi-
tions were also tested. Stronger retention due to the p-p
bonding was observed when using a PFP column compared
with C18 and C18-XB columns for all the studied com-
pounds. This effect was especially pronounced for opiates
and opioids, amphetamines, antipsychotics, and antidepres-
sants. On the other hand, cannabinoids, antiepileptics, and
benzodiazepines were eluted faster with a PFP column com-
pared with C18 or C18-XB columns. Antidepressants and
benzodiazepines showed similar chromatographic character-
istics with the three columns. As it is shown in Fig. 5, am-
phetamines presented peak area asymmetry using the C18 and
C18-XB columns, with a strong peak fronting effect
(Fig. 5b, c). The PFP column was more appropriate for these
compounds, providing higher sensitivity and more symmetric
peaks for amphetamines and compounds containing –NH2 or
–NH– groups (Fig. 5a). The PFP column provided also high
resolution and sensitivity, along with minimal peak asymme-
try, for sympathomimetics (Fig. 5d). In contrast, C18 columns
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Fig. 3 Recoveries organized in ranges for the target analytes using
Strata-XC (influent wastewater: spiked concentration, 1 μg/L; sample
volume, 50 mL)
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led to peak tailing and low sensitivity for these compounds
(Fig. 5e). Similar behavior was also observed for opiates and
opioids. In conclusion, better results were obtained using the
PFP column for most compounds, and it was the chosen
column to perform further experiments. However, it is neces-
sary to point out that the comparison was carried out with
columns of different lengths and particularly different particle
diameters that may have an influence in the performance of
the chromatography. Some exceptions were the mid-polar
antipsychotics olanzapine and norclozapine, which showed
better peak shape with the C18 columns. However, sensitivity
was further improved for these compounds by adjusting the
gradient of the optimum mobile phase.
Several mobile-phase combinations were tested for the PI
mode experiments, using MeOH and ACN as organic sol-
vents. Different concentrations of formic acid (organic modi-
fier) were also tested to determine the best conditions to obtain
a maximum peak resolution and little signal suppression.
Electronic Supplementary Material Fig. S1 shows how the
different mobile phases affect the peak area of the studied
analytes. Different behaviors towards the different conditions
were observed. In general, the addition of formic acid in-
creased the peak areas of many compounds (e.g., above
50 % in the case of benzodiazepine), because it facilitates
the positive ionization. Formic acid also significantly im-
proved the peak shapes for most analytes. For most families
of compounds (opioids and opiates, cocaine compounds, an-
tidepressants, anesthetics, benzodiazepines, amphetamine
compounds, antiepileptics), methanolic mobile phases provid-
ed better results, improving the chromatographic resolution
compared to ACN. Some exceptions can be found in the SSRI
antidepressants fluoxetine and paroxetine and the antipsy-
chotics family, where ACN improved the peak shape of all
the compounds in the group. Finally, reaching a compromise,
the best results were obtained using MeOH and Milli-Q water
(both containing 0.05 %v/v formic acid), allowing a satisfac-
tory elution for all the studied compounds (Electronic
Supplementary Material Fig. S1). Retention times for all the
compounds are detailed in Table 2. In the NI mode, the best
chromatographic conditions were achieved using MeOH and
Milli-Q water without the use of formate buffer or formic acid.
Column operational temperature (column oven) was also op-
timized. Different temperatures (from 25 to 50 °C) were
tested, although in general, no significant effects were ob-
served in the sensitivity of the analytes. A temperature of
25 °C proved to be the optimum column temperature since
some compounds (e.g., methadone, EDDP, oxycodone, co-
caine, clobazam, risperidone, imipramine, mirtazapine,
venlafaxine, fluoxetine, sertraline, and norsertraline and
norephedrine among others) showed better sensitivity.
MS/MS parameter optimization
MS/MS operational parameters were determined and opti-
mized by direct injection (infusion) experiments of individual
standard solutions. The first issue was to address the selection
of the ionization mode (ESI) that enhances the formation of
the protonated or deprotonated adduct in the ionization source
for each target compounds and IS. In general, most com-
pounds showed more efficient ionization in the PI mode,
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Fig. 4 Influence on the recovery
efficiency of the different
cartridges tested (Strata-X and
Strata-XC) for selected
compounds (influent wastewater:
spiked concentration, 1 μg/L;
sample volume, 50 mL)
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although for some of them, ionization in both modes is pos-
sible (e.g., THC and derivatives and topiramate). Thus, the
resulting method includes 63 compounds in the PI mode and 5
in the NI mode. For all the compounds determined in the PI
mode, the precursor ion was [M+H]+ except for topiramate.
For this compound, the intensity of the protonated adduct was
very low, and the intense and reproducible sodium adduct
[M+Na]+ (RSD<15%) was selected to perform the analysis.
In the NI mode, all the precursor ions corresponded to the
deprotonated molecule [M−H]−. Topiramate was also ionized
in the NI mode, but the signal was 25-fold lower than that
obtained in the PI mode. ESI conditions in both the PI and NI
modes were obtained as a compromise using the optimum
values for most compounds. These conditions are described in
detail in Electronic Supplementary Material Table S2. Table 2
summarizes the optimized values of MS/MS parameters for
the studied compounds. Tube lens voltageswere optimized for
each compound in order to enhance the formation of the
corresponding pseudo-molecular ion, to enhance desolvation,
and to prevent in-source fragmentation. The product ions (two
for each compound) were identified; two SRM transitions per
compound (quantification and confirmation) were selected,
and collision energies were optimized. Fragmentation patterns
of all the substances, including metabolites, were also studied.
This information is detailed in the Electronic Supplementary
Material Table S3.
Method validation
The performance of the method was evaluated under the
optimized conditions in terms of linearity range, sensitivity,
accuracy, repeatability, and ME. Instrumental analytical pa-
rameters, linearity ranges, correlation coefficients (r2), and
intraday instrumental precision, expressed as RSD, were
evaluated. The calibration curves obtained for the SRM tran-
sitions were linear for all the compounds in a wide range of
Fig. 5 Comparison of
chromatograms for
amphetamines and
sympathomimetics using different
columns. In all cases, the mobile
phase consists in MeOH/Milli-Q
water, 0.05 %v/v formic acid. a
Amphetamines with PFP column.
b Amphetamines with C18
column. c Amphetamines with
C18-XB column. d
Sympathomimetics with PFP
column. e Sympathomimetics
with C18 column. f
Sympathomimetics with C18-XB
column
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concentrations, typically from 0.1 to 100 μg/L with r2>
0.9978 for all compounds. Good instrumental precision was
obtained with RSD values in the range of 3–5 % (intraday
precision).
The method was validated for effluent and influent waste-
water samples. Table 2 summarizes the method performance
parameters for each compound. Quantification was based on
standard additions, and deuterated internal standards were
used only for the quantification of those compounds in which
isotopically labeled analogs were available. The use of deu-
terated analogs was imperative for THC and THCA due to
significant losses during sample preparation.
Extraction recoveries for target compounds were deter-
mined (n=6) at one concentration of 1.0 μg/L for both IWW
and EWW, mainly because many compounds were already
present in the samples, and a direct comparison of recoveries
between the two matrices was possible. Recoveries were
determined by comparing the concentrations obtained after
the whole procedure (pre-extraction spike) with the initial
spiking levels in matrix extract (post-extraction spike). As real
samples already contained the target compounds, nonspiked
samples were analyzed in order to determine their concentra-
tions, which were afterwards subtracted from the spiked sam-
ples. Recovery values ranged from 80 to 120 % for the more
than 80 % of target compounds in both IWW and EWW. In
general, polar compounds showed high recovery values due to
the ionic interactions with the sulfonic moiety of the Strata-XC
cartridge sorbent. For cannabinoids, low recoveries were ob-
tained due to the strong adsorption of these substances to the
Strata-XC particles, and due to the pi-stacking interactions
between their aromatic ring and the electron deficiency of the
benzene ring attached to the sulfonic acid moiety. Some authors
have also proposed sorption to glassware as a factor to explain
the low recoveries of these compounds [51]. It significantly
hinders the elution of these compounds, even if an acidic
washing step is included. These difficulties have been previ-
ously reported by Huq et al. [50]. Recovery values for the
compounds morphine, MDMA, benzoylecgonine, ketamine,
cocaine, LSD, EDDP, methadone, fluoxetine, temazepam, and
diazepam were higher than those reported by Bones et al. by
using Strata-XC cartridges [26] and similar to those reported by
Baker et al. by using Oasis MCX for amphetamines, benzodi-
azepines, opioids, and hallucinogenics [38]. TheMLODs (low-
est analyte concentration with a signal to noise (S/N) ratio of 3)
and the MLOQ (concentration with S/N ratio of 10 and impre-
cision lower than 20%)were calculated by analyzing five times
the lowest spiked concentration (0.01 μg/L for most com-
pounds). MLOD values, summarized in Table 2, were less than
or equal to 1.5 ng/L for 26 compounds. Significantly low
MLOD values were achieved for nortriptyline, norclozapine,
9-OH risperidone, and sertraline, in the range of 0.04–0.08 ng/
L. Thirty-three compounds showed values between 1.5 and
10 ng/L, and only seven analytes showed higher values,
between 14 and 63 ng/L, except phenytoin (154 ng/L) and
valproic acid (186 ng/L). The MLOQs achieved are below the
reported concentrations and allow a reliable quantification of
these analytes in IWWand EWW samples.
The overall method repeatability was also evaluated by
spiking wastewater samples with 1.0 μg/L of each compound
(n=6). For 65 investigated compounds, RSD values were
below 21 %, and only for thiopental, phenytoin, and valproic
acid that RSD values were higher.
A severe matrix effect in the quantitative LC–MS/MS
analysis of drugs has been widely observed [52, 53]. The
ESI source is highly susceptible to other components present
in the matrix, which may result in a signal suppression or
enhancement. Matrix effect values are summarized in Table 2.
In most cases, signal suppression was observed, and only 16
compounds out of 68 showed signal enhancement (from 2 to
17 %). Forty-four out of the 68 analyzed compounds showed
matrix ionization suppression between −1 and −28 %, and
only eight compounds between −33 and −60 %. The robust-
ness of the method was also studied during the validation
procedure, testing different injection volumes and introducing
slight changes in the pH of the mobile phase, in the gradient
setting and in the temperature. As it was observed, these
changes did not influence significantly the retention times or
the sensitivity. SRM chromatograms of all the compounds in a
spiked wastewater sample are presented in Electronic
Supplementary Material Table S5.
Application to real samples
The occurrence of the selected illicit and psychiatric drugs in
IWWand EWW from fiveWWTPs located in Santorini Island
was evaluated using the multi-residue method described
above. Sampling details have already been described in the
“Materials and methods” section. Concentration values of the
target compounds analyzed are summarized in Fig. 6 and
Electronic Supplementary Material Table S4. Both drugs of
abuse and psychiatric drugs were detected in all the processed
samples; 58 out of the 68 compounds were detected at least in
one sample, and 32 out of the 68 compounds investigated
were detected in all IWWand 22 in EWWwith very different
ranges. The compounds imipramine, thiopental, olanzapine,
fentanyl, chlorpromazine, 6-MAM, MDA, MA, chlordiaz-
epoxide, and nitrazepam were not detected in any sample.
Figure 6 shows the contribution of the different families of
compounds to each sample of both IWW and EWW. The
detailed concentrations are available in Electronic
Supplementary Material Table S4. The high contribution of
antiepileptics is highlighted, denoting the high use of these
pharmaceuticals. Of particular interest are the high values for
carbamazepine, levetiracetam, and valproic acid determined
for both IWWand EWW, with concentrations above 6 μg/L in
some cases. The high values of ephedrine in IWW (the only
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sympathomimetic that was detected) were also very relevant,
with concentrations up to 6.7 μg/L. Lower concentrations (but
still significant) were detected in EWW for this compound.
Antidepressants were also widely present in all the studied
samples; the TCAs amitriptyline and doxepin and the TeCA
mirtazapine showed the highest values, above 500 ng/L in
some samples. Also, SSRIs and SNRIs were detected,
citalopram and venlafaxine being the most relevant with
values up to 733 ng/L. These values are in agreement with
those of previous reports from Spain and Canada [22, 54].
High consumption of the illicit drugs cocaine and THCwas
determined since high concentrations of the metabolites of
these compounds were observed. BECG and EME and THCA
were determined in all the WWTP locations, along with their
parent compounds. LSD concentrations were very low. This
fact can be explained: LSD doses are in the order of micro-
grams (instead of milligrams as for the other drugs), and also,
LSD is intensively metabolized before excretion, giving as
major excretion products LSD, nor-LSD, and OH-LSD,
which was detected in relatively high concentrations in all
samples (22–54 ng/L), indicating the consumption of this
illicit drug. Low concentrations for MDMA and its metabolite
MDEAwere also determined.
Opiates, opioids, and their metabolites were detected in
IWW of the most populated areas Kamari, Fira, and
Karterados. However, no significant differences were ob-
served in general between the levels in the different
WWTPs, indicating a relevant consumption of these sub-
stances throughout the whole island.
For some compounds (e.g., OH-LSD, nordiazepam), it was
observed that concentrations were higher in the EWW than in
its corresponding IWW. This fact can be explained by the
formation of unmeasured products of human metabolism and/
or transformation products (e.g., glucuronide conjugate, meth-
ylates, glycinates, etc.) that are passing through the plant
converting back to the parent compounds. This can be con-
sidered as a reasonable assumption since the metabolites and
some derivates of the mentioned compounds are well known
(e.g., hydroxyl- and epoxy-derivatives of carbamazepine)
[55]. However, it is important to consider that the samples
analyzed were grab samples. Results indicated high consump-
tion of these substances, but do not allow drawing sound long-
term conclusions.
Conclusions
The present work reports the development and validation of
a new analytical methodology for the simultaneous analysis
of 68 compounds, including psychiatric drugs, illicit drugs,
and some selected human metabolites (substances with a
wide range of psychochemical properties) based on LC–
MS/MS using a PFP chromatographic column. A SPE step
based on RP-cation exchange Strata-XC cartridges provid-
ed the best results. The multi-residue method proved to be
highly sensitive (MLODs ranged from 0.04 to 10.0 ng/L for
86.7 % of the compounds), allowing its use for monitoring
the presence of the target analytes in real wastewater.
Absolute recovery rates obtained ranged from 80 to
120 % for most compounds (55 out of 68). Good results
were obtained for EME, which is a significant metabolite of
cocaine and necessary in order to obtain additional con-
sumption data of this drug. The method was applied for the
analysis of the selected drugs in wastewaters from five
different networks located in Santorini Island (Cyclades
Islands, Central Aegean Sea, Greece) during the peak tour-
ist season. Results shows the high consumption of some
illicit drugs including cocaine, methadone, ecstasy, LSD,
and THC, confirmed by the presence of some metabolites
such as EME, BECG, EDDP, MDME, LSD-OH, and
THCA. The presence of high levels of psychiatric drugs
including carbamazepine, valproic acid, levetiracetam,
ephedrine, venlafaxine, oxazepam, amitriptyline doxepin,
and oxazepam among others, was also assessed. Results
also confirm the presence of most of these drugs in EWWat
relevant concentrations, showing that the treatments ap-
plied in the selected WWTP are not effective enough for
the complete removal of these compounds, and significant
amounts of these substances are released to the marine
environment in this case.
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